Regen BioPharma, Inc., (OTCQB: RGBP) and (OTCQB: RGBPP) announced today that the Pan Am Cancer Treatment Center in Tijuana, Mexico presented final clinical data on their first 5 patients. Beginning in March 2016, 5 patients with chemotherapy-induced bone marrow suppression were treated with HemaXellerate and initial 1 month follow up data were provided. Pan Am Cancer Treatment Center has now provided 3 and 6 month follow up data in these same patients. The primary endpoint of the study is safety and the secondary endpoint is effectiveness. Pan Am Cancer Treatment Center has been granted a non-exclusive license to test HemaXellerate in a first-in-human proof of concept study.
